MI Jun
Email: jmei@sjtu.edu.cn
Tel: 021-63846590-776491
Research Interest: 1. Effects of microenvironmental metabolites on tumor progression and treatment, focusing on metabolites as signal molecules regulating therapeutic resistance and tumor immune evasion. 2. The clinical applications of tumor metabolites, such as metabolites or enzymes as diagnostic or prognostic markers and therapeutic targets.
Biography
Mi Lab has been devoted to studying tumor pathogenesis and early diagnosis for many years and has achieved remarkable results. 3-HAA binding of YY1 leads to phosphorylation of YY1 at the Thr 398 by PKCζ, concomitantly enhancing YY1 chromatin binding activity to increase the expression of target genes. 3-HAA down-regulates AKT and Wnt signaling, consequently inhibiting the growth of HCC cells. 3-HAA sensitizes HCC cells to sorafenib by reducing tumor stemness. In addition, upstream regulatory proteins PP6 and VCP regulate DNA-PK's activity and protein stability, respectively. The regulation enhances the radiosensitivity of glioma cells.
Moreover, cytokines such as TGF-β secreted by tumor cells induce primary fibroblasts to form cancer-associated fibroblasts (CAF) and macrophages to form tumor-associated macrophages (TAM), respectively. The miR-21/Smad 7 signaling role in fibroblasts activation and tumor progression. We have published more than 30 papers in J. Hematol Oncol, Cancer Res, et al. peer-viewed journals. Furthermore, we have undertaken more than ten research projects, supported by the Shanghai and national scientific funds, with over 10 million RMB. We have applied for two international invention patents and won the second prize in the Chinese Medical Science and Technology Award.
Education experience
2001, Molecular Biology, Shanghai Second Medical University, Doctoral degree
Work experience:
2001-2005, University of Virginia, Postdoctoral Researcher
2005-2008, University of Virginia, Research Assistant Professor
2009-Present, Shanghai Jiao Tong University School of Medicine, Principal Investigator, Professor, Doctoral supervisor
Ongoing Projects:
(1) Project name: The effect and mechanism of 3-hydroxyanthranilic acid (3-HAA)-induced apoptosis of liver cancer cells (NSFC, No. 82073040)
(2) Project Name: Research on New Technologies and New Strategies of Radiotherapy for Malignant Tumors (Key Special Project of the Ministry of Science and Technology, No.: 2018YFC1313205)
(3) Project name: Study on the mechanism of alanine aminotransferase GPT2 promoting breast cancer metastasis by regulating glutamate metabolism (NSFC, No. 81872342)
Representative Publications
Shi Z, Gan G, Gao X, Chen F, Mi J. Kynurenine catabolic enzyme KMO regulates HCC growth. Clin Transl Med. 2022 Feb;12(2):e697.
Shi Z, Gan G, Xu X, Zhang J, Yuan Y, Bi B, Gao X, Xu P, Zeng W, Li J, Ye Y, Zhou A, Zhang N, Liu W, Lin S, Mi J. Kynurenine derivative 3-HAA is an agonist ligand for transcription factor YY1. J Hematol Oncol. 2021 Sep 25;14(1):153.
Gan G, Shi Z, Liu D, Zhang S, Zhu H, Wang Y, Mi J. 3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness. Cell Death Discov. 2021 Jul 6;7(1):173.
Xu X, Li N, Wang Y, Yu J, Mi J. Calcium channel TRPV6 promotes breast cancer metastasis by NFATC2IP. Cancer Lett. 2021 Oct 28;519:150-160.
Cui M, Liu D, Xiong W, Wang Y, Mi J. ERRFI1 induces apoptosis of hepatocellular carcinoma cells in response to tryptophan deficiency. Cell Death Discov. 2021 Oct 4;7(1):274.
Gan G, Shi Z, Shangguan C, Zhang J, Yuan Y, Chen L, Liu W, Li B, Meng S, Xiong W, Mi J. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases. Theranostics. 2021 Apr 3;11(12):6006-6018.
Zhang J, Shi Z, Xu X, Yu Z, Mi J. The influence of microenvironment on tumor immunotherapy. FEBS J. 2019 Nov;286(21):4160-4175.
Shangguan C, Gan G, Zhang J, Wu J, Miao Y, Zhang M, Li B, Mi J. Cancer-associated fibroblasts enhance tumor 18F-FDG uptake and contribute to the intratumor heterogeneity of PET-CT. Theranostics. 2018 Feb 2;8(5):1376-1388.
Wang Y, Fu L, Cui M, Wang Y, Xu Y, Li M, Mi J. Amino acid transporter SLC38A3 promotes metastasis of non-small cell lung cancer cells by activating PDK1. Cancer Lett. 2017 May 1;393:8-15.
10. Wang Y, Gan G, Wang B, Wu J, Cao Y, Zhu D, Xu Y, Wang X, Han H, Li X, Ye M, Zhao J, Mi J. Cancer-associated Fibroblasts Promote Irradiated Cancer Cell Recovery Through Autophagy. EBioMedicine. 2017 Mar;17:45-56.
Jiang Y, Cao Y, Wang Y, Li W, Liu X, Lv Y, Li X, Mi J. Cysteine transporter SLC3A1 promotes breast cancer tumorigenesis. Theranostics. 2017 Feb 26;7(4):1036-1046.
Cao Y, Lin SH, Wang Y, Chin YE, Kang L, Mi J. Glutamic Pyruvate Transaminase GPT2 Promotes Tumorigenesis of Breast Cancer Cells by Activating Sonic Hedgehog Signaling. Theranostics. 2017 Jul 22;7(12):3021-3033.
Wu J, Fu R, Liu Z, Li G, Huang X, Xue Y, Xu Y, Sun Y, Zhao J, Mi J. Cell proliferation downregulated by TGF-β2-triggered G1/S checkpoint in clinical CAFs. Cell Cycle. 2017 Jan 17;16(2):172-178.
Zhang D, Wang Y, Shi Z, Liu J, Sun P, Hou X, Zhang J, Zhao S, Zhou BP, Mi J. Metabolic reprogramming of cancer-associated fibroblasts by IDH3α downregulation. Cell Rep. 2015 Mar 3;10(8):1335-48.
Xing Y, Zhao S, Zhou BP, Mi J. Metabolic reprogramming of the tumour microenvironment. FEBS J. 2015 Oct;282(20):3892-8.
Patent
Method for detecting tumor tissue bound aries or tumor stromal cell distribute range. Patent for invention, Patent Application No. 201610615329.8。
The combination of 3-hydroxyaminobenzoic acid and Sorafenib in the treatment of tumor. Patent for invention, Patent Application No. 201810639339.4。
